Last reviewed · How we verify
Tinzaparin bolus
Tinzaparin bolus is a Small molecule drug developed by Tampere University Hospital. It is currently FDA-approved.
Tinzaparin is an antithrombin-III activator, a type of oligosaccharide drug that belongs to the ACTIVATOR class. It is used to treat conditions such as acute myocardial infarction, pulmonary embolism, and thromboembolism, among others.
At a glance
| Generic name | Tinzaparin bolus |
|---|---|
| Sponsor | Tampere University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke (PHASE2)
- Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation
- The Effect of Prophylactic Anticoagulation on Major Bleeding Events in Hospitalized Chronic Kidney Disease and Lower Limb Fracture Patients. (PHASE2)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) (PHASE3)
- Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tinzaparin bolus CI brief — competitive landscape report
- Tinzaparin bolus updates RSS · CI watch RSS
- Tampere University Hospital portfolio CI
Frequently asked questions about Tinzaparin bolus
What is Tinzaparin bolus?
Who makes Tinzaparin bolus?
What development phase is Tinzaparin bolus in?
Related
- Manufacturer: Tampere University Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing